Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Unknown 1

Sponsor Class

OTHER 1INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 648Thoracic 198Genitourinary 155Lymphoid 113Breast 99Head & Neck 82Gynecologic 60Sarcoma 58Tumor-Agnostic 30Other solid neoplasm 28Other hematologic neoplasm 14CNS 13Dermatologic 10Plasma cell 8Myeloid 4Endocrine 1Classical hematology 1

Conditions

Stomach Neoplasms 1Small Cell Lung Carcinoma 1Carcinoma, Non-Small-Cell Lung 1Carcinoma, Neuroendocrine 1

Interventions

lutetium Lu 177 dotatate 36Everolimus 32pembrolizumab 24Temozolomide 21Magnetic Resonance Spectroscopy 21Nivolumab 18lenvatinib 17gallium Ga 68 dotatate 16cabozantinib 15Cisplatin 15lanreotide 143-Iodobenzylguanidine 14Capecitabine 13trametinib 12dabrafenib 12Bevacizumab 12Octreotide 11Surveys and Questionnaires 10Surgical Procedures, Operative 10Sunitinib 10Radiosurgery 10Positron Emission Tomography Computed Tomography 10Blood Specimen Collection 10Sorafenib 9Paclitaxel 9Ipilimumab 9Carboplatin 9surufatinib 8Etoposide 8Doxorubicin 8

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
OTHER × Gemcitabine × Endocrine × Clear all
NCT00178698 2011-03-03

FR-WB-TT/che

The University of Texas Health Science Center, Houston

Phase 2 Unknown
36 enrolled
EndocrineGastrointestinalThoracic

Carcinoma, Non-Small-Cell Lung, Stomach Neoplasms, Carcinoma, Neuroendocrine, Small Cell Lung Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡